Search

Your search keyword '"Nikiforow, Sarah"' showing total 140 results

Search Constraints

Start Over You searched for: Author "Nikiforow, Sarah" Remove constraint Author: "Nikiforow, Sarah" Database ScienceDirect Remove constraint Database: ScienceDirect
140 results on '"Nikiforow, Sarah"'

Search Results

1. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

2. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival

5. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

6. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

11. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

13. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies

18. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

19. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

21. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

26. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

29. BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

31. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

32. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

33. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation

34. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

35. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

38. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy

39. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma

41. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients

43. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

47. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Catalog

Books, media, physical & digital resources